Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.00.

A number of brokerages have recently weighed in on ZNTL. Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research note on Monday, August 12th.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of ZNTL. Values First Advisors Inc. raised its holdings in Zentalis Pharmaceuticals by 5.4% during the 2nd quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock valued at $306,000 after acquiring an additional 3,859 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the period. Carson Advisory Inc. raised its holdings in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock valued at $90,000 after acquiring an additional 8,800 shares during the period. Anfield Capital Management LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $40,000. Finally, Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000.

Zentalis Pharmaceuticals Trading Down 8.2 %

ZNTL stock opened at $3.36 on Friday. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07. The business has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $4.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.